Search
for
Sort by
Research 571–600 of 1000+
- Risk Factors and Characterization of Vitiligo and Alopecia Areata in Patients With Chronic Graft-vs-Host Disease
- Photobiomodulation for the management of hair loss
- Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy
- Ejaculatory dysfunction in the treatment of lower urinary tract symptoms
- Alopecia in patients with COVID-19: A systematic review and meta-analysis
- Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
- Analysis of dermatology-related search engine trends during the COVID-19 pandemic: Implications for patient demand for outpatient services and telehealth
- Impaired Hair Growth and Wound Healing in Mice Lacking Thyroid Hormone Receptors
- Bendamustine in Indolent Non-Hodgkin's Lymphoma: A Practice Guide for Patient Management
- Patient’s experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritis
- Estimated serum vitamin D status, vitamin D intake, and risk of incident alopecia areata among US women
- Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities
- Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours
- Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience
- Sebaceous immunobiology - skin homeostasis, pathophysiology, coordination of innate immunity and inflammatory response and disease associations
- Alopecia Areata: An Update on Treatment Options for Children
- Cutaneous Lesions in the Rat Following Administration of an Irreversible Inhibitor of erbB Receptors, Including the Epidermal Growth Factor Receptor
- British Association of Dermatologists living guideline for managing people with alopecia areata 2024
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
- The associated burden of mental health conditions in alopecia areata: a population‐based study in UK primary care*
- Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial
- International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women
- IL-12/IL-23 neutralization is ineffective for alopecia areata in mice and humans
- Effective use of ustekinumab in a patient with concomitant psoriasis, vitiligo, and alopecia areata
- Social media for arthritis-related comparative effectiveness and safety research and the impact of direct-to-consumer advertising
- JAK inhibition decreases the autoimmune burden in Down syndrome
- Prevalence of alopecia areata in Japan: Estimates from a nationally representative sample
- Glucocorticoids and Risk of Venous Thromboembolism in Asthma Patients Aged 20–59 Years in the United Kingdom’s CPRD 1995–2015
- A phase 2a trial of brepocitinib for cicatricial alopecia
- Psychosocial and mental impact of alopecia areata: Analysis of the Danish Skin Cohort